Home/Filings/4/0000905148-25-001058
4//SEC Filing

Hyllengren Eric J 4

Accession 0000905148-25-001058

CIK 0001604464other

Filed

Apr 1, 8:00 PM ET

Accepted

Apr 2, 7:54 PM ET

Size

24.6 KB

Accession

0000905148-25-001058

Insider Transaction Report

Form 4
Period: 2025-03-31
Hyllengren Eric J
EVP, CFO and COO
Transactions
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2025-03-314960 total
    Exercise: $303.75From: 2023-04-01Exp: 2030-02-28Common Stock (496 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2025-03-311540 total
    Exercise: $303.75Exp: 2030-02-28Common Stock (154 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2025-03-313810 total
    Exercise: $427.63From: 2023-04-01Exp: 2031-02-28Common Stock (381 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2025-03-312620 total
    Exercise: $255.25From: 2023-04-01Exp: 2032-02-29Common Stock (262 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2025-03-311,9000 total
    Exercise: $996.25From: 2022-08-20Exp: 2025-09-03Common Stock (1,900 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2025-03-314600 total
    Exercise: $961.75From: 2023-02-06Exp: 2029-02-05Common Stock (460 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2025-03-313500 total
    Exercise: $427.63Exp: 2031-02-28Common Stock (350 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2025-03-31543160 total
    Exercise: $255.25Exp: 2032-02-29Common Stock (543 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2025-03-313310 total
    Exercise: $97.75From: 2023-04-01Exp: 2033-02-28Common Stock (331 underlying)
  • Disposition to Issuer

    Employee Stock Option (Right to Buy)

    2025-03-318,9612,656 total
    Exercise: $97.75Exp: 2033-02-28Common Stock (8,961 underlying)
Footnotes (4)
  • [F1]1/11th of the shares subject to the stock option vested and became exercisable on May 1, 2023, and the remaining shares vested in equal monthly installments over the following ten (10) months, subject to the reporting person's continuous service.
  • [F2]1/23rd of the shares subject to the stock option vested and became exercisable on May 1, 2023, and the remaining shares vested in equal monthly installments over the following twenty-two (22) months, subject to the reporting person's continuous service.
  • [F3]1/35th of the shares subject to the stock option vested and became exercisable on May 1, 2023, and the remaining shares vest in equal monthly installments over the following thirty-four (34) months, subject to the reporting person's continuous service.
  • [F4]This option was cancelled by mutual agreement of the Issuer and the reporting person, in exchange for which cancellation the reporting person will receive a total cash payment of $100 as consideration.

Documents

1 file

Issuer

Atara Biotherapeutics, Inc.

CIK 0001604464

Entity typeother

Related Parties

1
  • filerCIK 0001966926

Filing Metadata

Form type
4
Filed
Apr 1, 8:00 PM ET
Accepted
Apr 2, 7:54 PM ET
Size
24.6 KB